GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verseon Corp (GREY:VERS) » Definitions » ROCE %

Verseon (Verseon) ROCE % : -47.07% (As of Jun. 2019)


View and export this data going back to 2016. Start your Free Trial

What is Verseon ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Verseon's annualized ROCE % for the quarter that ended in Jun. 2019 was -47.07%.


Verseon ROCE % Historical Data

The historical data trend for Verseon's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verseon ROCE % Chart

Verseon Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
ROCE %
Get a 7-Day Free Trial - -18.43 -26.19 -36.17 -42.84

Verseon Semi-Annual Data
Dec11 Dec12 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -29.21 -44.45 -36.62 -39.54 -47.07

Verseon ROCE % Calculation

Verseon's annualized ROCE % for the fiscal year that ended in Dec. 2018 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2018 )  (A: Dec. 2017 )(A: Dec. 2018 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2018 )  (A: Dec. 2017 )(A: Dec. 2018 )
=-21.298/( ( (54.155 - 6.368) + (56.359 - 4.719) )/ 2 )
=-21.298/( (47.787+51.64)/ 2 )
=-21.298/49.7135
=-42.84 %

Verseon's ROCE % of for the quarter that ended in Jun. 2019 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2019 )  (Q: Dec. 2018 )(Q: Jun. 2019 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2019 )  (Q: Dec. 2018 )(Q: Jun. 2019 )
=-24.196/( ( (56.359 - 4.719) + (57.616 - 6.439) )/ 2 )
=-24.196/( ( 51.64 + 51.177 )/ 2 )
=-24.196/51.4085
=-47.07 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2019) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Verseon  (GREY:VERS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


Verseon ROCE % Related Terms

Thank you for viewing the detailed overview of Verseon's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Verseon (Verseon) Business Description

Traded in Other Exchanges
N/A
Address
47071 Bayside Parkway, Fremont, CA, USA, 94538
Verseon Corp is a part of the healthcare sector in the United States. It is a technology-based pharmaceutical company with a computer-driven drug discovery platform. The company designs novel drug candidates that are unlikely to be found using conventional methods. It is also engaged in drug discovery programs such as the diabetic macular edema product candidates, which treat the diseases by controlled disruption of the kallikrein kinin cascade.

Verseon (Verseon) Headlines